The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor:In vivo expression and antitumor activity
Open accessAbstract
Neuropilin-1 (NRP1) is a 130-kDa transmembrane receptor for semaphorins, mediators of neuronal guidance, and for vascular endothelial growth factor 165 (VEGF 165), an angiogenesis factor. A 2.2-kb truncated NRP1 cDNA was cloned that encodes a 644-aa soluble NRP1 (sNRP1) isoform containing just the a/CUB and b/coagulation factor homology extracellular domains of NRP1. sNRP1 is secreted by cells as a 90-kDa protein that binds VEGF 165, but not VEGF 121. It inhibits 125 I-VEGF 165 binding to endothelial and tumor cells and VEGF 165-induced tyrosine phosphorylation of KDR in endothelial cells. The 3′ end of sNRP1 cDNA contains a unique, 28-bp intron-derived sequence that is absent in full-length NRP1 cDNA. Using a probe corresponding to this unique sequence, sNRP1 mRNA could be detected by in situ hybridization differentially from full-length NRP1 mRNA, for example, in cells of liver, kidney, skin, and breast. Analysis of blood vessels in situ showed that NRP1, but not sNRP1, was expressed. sNRP1 was functional in vivo. Unlike control tumors, tumors of rat prostate carcinoma cells expressing recombinant sNRP1 were characterized by extensive hemorrhage, damaged vessels, and apoptotic tumor cells. These results demonstrate the existence of a naturally occurring, soluble NRP1 that is expressed differently from intact NRP1 and that appears to be a VEGF 165 antagonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,463
Self-citationPlate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,275
Kendall, R. L., & Thomas, K. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10705 · Cited by 1,394
In situ hybridization; a practical approach
(1993) · International Journal of Biochemistry · doi:10.1016/0020-711x(93)90093-t · Cited by 1,220
Neuropilin Is a Semaphorin III Receptor
Kolodkin, A. L., Levengood, D. V., Rowe, E. G., Tai, Y.-T., Giger, R. J., & Ginty, D. D. (1997) · Cell · doi:10.1016/s0092-8674(00)80535-8 · Cited by 1,180
Neuropilin Is a Receptor for the Axonal Chemorepellent Semaphorin III
He, Z., & Tessier-Lavigne, M. (1997) · Cell · doi:10.1016/s0092-8674(00)80534-6 · Cited by 1,142
Kendall, R. L., Wang, G., & Thomas, K. A. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1355 · Cited by 724
Vascular endothelial growth factor and its receptors
Klagsbrun, M., & A. D'Amore, P. (1996) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(96)00027-5 · Cited by 682
Self-citationBenjamin, L. E., & Keshet, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8761 · Cited by 506
Gitay-Goren, H., Soker, S., Vlodavsky, I., & Neufeld, G. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42666-x · Cited by 490
Self-citationDvorak, H. F., Sioussat, T. M., Brown, L. F., Berse, B., Nagy, J. A., Sotrel, A., Manseau, E. J., Van de Water, L., & Senger, D. R. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.5.1275 · Cited by 483
Neuropilin-1 Mediates Collapsin-1/Semaphorin III Inhibition of Endothelial Cell Motility
Miao, H.-Q., Soker, S., Feiner, L., Alonso, J. L., Raper, J. A., & Klagsbrun, M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.1.233 · Cited by 458
Self-citationGoldman, C. K., Kendall, R. L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G. Y., Siegal, G. P., Mao, X., Bett, A. J., Huckle, W. R., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8795 · Cited by 443
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
Millauer, B., Longhi, M. P., Plate, K. H., Shawver, L. K., Risau, W., Ullrich, A., & Strawn, L. M. (1996) · PubMed · Cited by 413
Kitsukawa, T., Shimono, A., Kawakami, A., Kondoh, H., & Fujisawa, H. (1995) · Development · doi:10.1242/dev.121.12.4309 · Cited by 410
Isaacs, J. T., Isaacs, W. B., Feitz, W. F. J., & Scheres, J. (1986) · The Prostate · doi:10.1002/pros.2990090306 · Cited by 407
Johnson, D. E., Lu, J., Chen, H., Werner, S., & Williams, L. T. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.9.4627 · Cited by 404
Giger, R. J., Urquhart, E. R., Gillespie, S. K. H., Levengood, D. V., Ginty, D. D., & Kolodkin, A. L. (1998) · Neuron · doi:10.1016/s0896-6273(00)80625-x · Cited by 349
Soker, S., Fidder, H., Neufeld, G., & Klagsbrun, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5761 · Cited by 343
Self-citationKawakami, A., Kitsukawa, T., Takagi, S., & Fujisawa, H. (1996) · Journal of Neurobiology · doi:10.1002/(sici)1097-4695(199601)29:1<1::aid-neu1>3.0.co;2-f · Cited by 291
Klagsbrun, M., & Moses, M. A. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80081-7 · Cited by 237
Self-citationLin, P. C., Sankar, S., Shan, S. Q., Dewhirst, M. W., Polverini, P. J., Quinn, T. Q., & Peters, K. G. (1998) · PubMed · Cited by 199
Petch, L. A., Harris, J., Raymond, V. W., Blasband, A., Lee, D. C., & Earp, H. S. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.6.2973 · Cited by 196
Gechtman, Z., Alonso, J. L., Raab, G., Ingber, D. E., & Klagsbrun, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.40.28828 · Cited by 181
Self-citationTakagi, S., Tsuji, T., Amagai, T., Takamatsu, T., & Fujisawa, H. (1987) · Developmental Biology · doi:10.1016/0012-1606(87)90335-6 · Cited by 164
Dong, Z., Greene, G. L., Pettaway, C. A., Dinney, C. P., Eue, I., Lu, W., BUCANA, C. D., Balbay, M. D., Bielenberg, D. R., & Fidler, I. J. (1999) · PubMed · Cited by 133
Self-citationRadinsky, R., Bucana, C. D., Ellis, L. M., Sanchez, R. R., Cleary, K. R., Brigati, D. J., & Fidler, I. J. (1993) · PubMed · Cited by 97
In Situ Hybridization: A Practical Approach
(1998) · doi:10.1093/oso/9780199636594.001.0001 · Cited by 70
Lee, H., & Maihle, N. J. (1998) · Oncogene · doi:10.1038/sj.onc.1201866 · Cited by 62
Gagnon, M. L., Moy, G. K., & Klagsbrun, M. (1999) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19990315)72:4<492::aid-jcb5>3.0.co;2-h · Cited by 23
Self-citation
Cited by
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Vascular endothelial growth factor (VEGF) signaling in tumor progression
Roskoski, R. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.01.006 · Cited by 599
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Harper, S. J., & Bates, D. O. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2505 · Cited by 514
Metadata
- Authors
- Gagnon, M. L., Bielenberg, D. R., Gechtman, Z., Miao, H.-Q., Takashima, S., Soker, S., & Klagsbrun, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-02-25
- Volume
- 97
- Issue
- 6
- Pages
- 2573-2578
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2022950801
- Cited by
- 313
- References
- 33
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.